Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
Guisier, Dubos-Arvis, Viñas, Doubre, Ricordel, Ropert, Janicot, Bernardi, Fournel, Lamy, Pérol, Dauba, Gonzales, Falchero, Decroisette, Assouline, Chouaid, Bylicki (2020) Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 J Thorac Oncol (IF: 20.4) 15(4) 628-636Links
http://www.ncbi.nlm.nih.gov/pubmed/31945494http://dx.doi.org/10.1016/j.jtho.2019.12.129
